India's largest biomedical event, 'Medical Innovations Patent Mitra: Innovators-to-Industry Connect', successfully took place in New Delhi....

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Quote of the Day: Melinda French Gates states that societies move backward when men make decisions for women. Her words champion equality a...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

April 12th holds significant weight in American history. It witnessed the start of the Civil War at Fort Sumter in 1861. President Franklin...

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Base...

NCP chief Sharad Pawar has proposed Cyrus Poonawalla, the founder of the Serum Institute of India (SII), for the prestigious Bharat Ratna a...

Several countries have already altered their advice after previous research indicated that, in rare number of cases, thrombosis with thromb...

The two countries have reaffirmed their commitment to facilitate joint research and information sharing to address barriers to pandemic-rel...

If the trial is successful, regulators could approve the vaccine for use in the last three months of the year, the drugmakers said in a sta...

What are the key challenges that will drive the longer-term change agenda? We would highlight three pivotal themes that will drive many oth...

The move will affect up to 40 million doses of the Oxford University-AstraZeneca vaccines being manufactured by the Serum Institute that we...

The increased caseload could lead to near-term growth concerns and delay market expectations on the timing of policy normalisation, global ...

The Nomura India Business Resumption Index (NIBRI) sharply picked up to 96.5 for the week ending February 7, from 94.4 in the previous week...

The country’s Covid-19 vaccination drive, which begins Saturday, is likely to cost 0.2-0.5% of gross domestic product (GDP), according to e...

The Japanese brokerage turned positive on India’s cyclical outlook, with near term risks of a resurgent pandemic unlikely to derail growth,...

Last week, Moderna announced the start of a late-stage trial on 30,000 people to demonstrate that its vaccine was safe and effective, the f...